Finanzen von LB Pharmaceuticals Inc (LBRX)LBRXLB Pharmaceuticals Inc

Evaluating the bottom line, LB Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -75.01%, provide a clear picture of how effectively LBRX converts its operational activities into shareholder value.

In the context of the broader market, LBRX competes directly with industry leaders such as OMER and NKTR. With a market capitalization of $1.25B, it holds a significant position in the sector. When comparing efficiency, LBRX's gross margin of N/A stands against OMER's 97.20% and NKTR's 100.00%. Such benchmarking helps identify whether LB Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company has experienced significant growth over the past year, with a 1-year change of +129.62%. Despite recent losses, the forward P/E is currently at 0, indicating potential for future profitability as the company develops its lead candidate, LB-102.